Optimum’s clients soak up the optimistic mood of 2024

The current optimistic mood in biotech was reflected in a string of positive announcements from Optimum and its clients. 

SynOx completes $75m Series B financing to fund cancer mAb 

SynOx Therapeutics Limited, the late-stage clinical biopharmaceutical company, on Monday announced the close of a $75m Series B financing. The financing was co-led by Forbion, HealthCap and new investor Bioqube Ventures. 

The proceeds will be used to generate registrational Phase 3 clinical and CMC data for emactuzumab, SynOx’s potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of Tenosynovial Giant Cell Tumour (TGCT). 

AMSilk strengthens management team with key hires 

AMSilk GmbH, a global leader in advanced materials made from spider silk-based proteins, on Tuesday announced the appointments of Ralph Fraundorfer and Ctibor Kohutovic to its Management Board starting immediately. 

Vivet Therapeutics’ management team hit the conference circuit 

Vivet Therapeutics announced on Tuesday that its management team will be participating and presenting at a series of scientific and business conferences in April, May and June. 

Highlights include presentations at the LSX 10th Annual World Congress on 29-30 April in London, the American Society of Gene and Cell Therapy on 7-11 May, in Baltimore, and Bio€quity Europe on 12-14 May in San Sebastian, Spain. 

Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors 

Flindr Therapeutics B.V., a precision oncology therapeutics company, on Wednesday announced a €20 million Series A financing to advance its pipeline of first-in-class, small molecule inhibitors for treatment of cancer.  

V-Bio Ventures led the financing alongside other new investors Johnson & Johnson Innovation – JJDC, Inc. (JJDC), QBIC Fund, Flanders Future Tech Fund and Curie Capital, as well as existing investors Oncode Oncology Bridge Fund, Swanbridge and Brabantse Ontwikkelings Maatschappij (BOM). 

Heidelberg Pharma AG: Interim Management Statement and promising early results from multiple myeloma drug 

Heidelberg Pharma AG, the antibody-drug conjugate specialist from Ladenburg, Germany, on Thursday gave an interim management statement detailing key developments in the first three months of 2024. 

Highlights included first efficacy data from the clinical trial of Amanitin-based antibody-drug conjugate HDP-101 in multiple myeloma, Professor Andreas Pahl taking over as CEO, and the sale of a portion of future royalties for Zircaix to HealthCare Royalty to finance further development of its pipeline. In a webinar to coincide with its management statement, CEO Pahl led a webinar outlining latest progress with HDP-101 in the clinic. 

The latest readout from a Phase 1a/2 trial in multiple myeloma paves the way for further trials. The lack of ocular toxicity seen in rival multiple myeloma drugs and promising signs of efficacy in several of the 18 patients means it is “ripe for further development”, according to Jonathan Kaufman, Associate Professor of Hematology and Medical Oncology at Emory University School of Medicine, in Atlanta. 

Calliditas Therapeutics’ 2023 Annual Report published 

Calliditas Therapeutics, the biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical needs, published its 2023 Annual Report on Thursday. 

Highlights included positive results from a confirmatory Phase 3 trial of Tarpeyo (budesonide) in primary IgA nephropathy (IgAN), which prompted a priority review and full FDA approval in December 2023. 

BII announces launch of Science Translational Medicine Prize for Innovations in Women´s Health and Gender Medicine 

BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, on Friday announced the launch of the BII & Science Translational Medicine Prize for Innovations in Women´s Health and Gender Medicine. 

This follows the successful BII & Science Prize for Innovation – which is now in its third year and recognizes and celebrates bold researchers internationally who are asking fundamental questions at the intersection of life sciences and entrepreneurship.